Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with FOLFOX for unresectable colorectal cancer liver metastases
ChiCTR1800014964Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Mar 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: R0 resection rate and Adverse events. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
Rivoceraniboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800014964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014964.